Ryan Scott

Articles

Sammons Spotlights Approaches Under Exploration for HER2+ Breast Cancer and Brain Metastases

February 19th 2024

Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.

Enfortumab Vedotin Plus Pembrolizumab Receives Priority Review in Japan for First-Line Urothelial Carcinoma

February 16th 2024

The sNDA for enfortumab vedotin-ejfv plus pembrolizumab in patients with metastatic urothelial cancer has received priority review in Japan.

FDA Approves AI-Powered Detection Device for Skin Cancers

February 16th 2024

The FDA has granted clearance for the first real-time, non-invasive skin cancer evaluation system .

Insights Into Pediatric Oncology on Childhood Cancer Day: Advances, Challenges, and Survivorship

February 15th 2024

Burton Eliot Appel, MD, discusses the landscape of pediatric oncology on International Childhood Cancer Day.

Real-World Analysis Sheds Light on Brain Metastases Incidence in HER2+ Breast Cancer

February 15th 2024

Sarah Sammons, MD, discusses what is known about the incidence of brain metastases in patients with breast cancer.

Breaking Boundaries: Advancements and Challenges in Treatment with ADCs in NSCLC

February 15th 2024

Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.

Unlocking the Potential: The Evolution of ADCs in HER2+ NSCLC

February 14th 2024

Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.

FDA Grants Fast Track Designation to CAN-3110 for Recurrent High-Grade Glioma

February 13th 2024

CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.

Retrospective Review Sheds Light on Real-World Efficacy With Teclistamab in R/R Myeloma After BCMA-Directed Therapy

February 8th 2024

Teclistamab produced responses in real-world patients with relapsed and refractory multiple myeloma and prior exposure to BCMA-targeted therapy.

HPN328 Shows Clinical Activity and Tolerability in Neuroendocrine Prostate Cancer

February 8th 2024

HPN328, was well tolerated and elicited responses in patients with neuroendocrine prostate cancer and other neuroendocrine neoplasms.

Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?

February 7th 2024

Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.

2023 Data Readouts Enable New Treatment Avenues in Oncogene-Driven NSCLC

February 7th 2024

Edgardo S. Santos Castillero, MD, FACP, spotlights some impactful trials in lung cancer that were discussed in 2023, including the phase 3 MARIPOSA-2 trial, and more.

Santos Breaks Down Key Updates From 2023 in the Management of EGFR-Mutant NSCLC

February 6th 2024

Edgardo S. Santos Castillero, MD, FACP, expands on outcomes from pivotal phase 3 trials such as ADAURA and FLAURA2 in patients with EGFR-mutant NSCLC.

FDA Grants Fast Track Designation to UV1 Cancer Vaccine for Unresectable/Metastatic Mesothelioma

February 5th 2024

The UV1 cancer vaccine received fast track designation for use in combination with ipilimumab and nivolumab for patients with unresectable malignant pleural mesothelioma.

World Cancer Day Highlights Ways to Address Gaps in Care for Black Patients With Breast Cancer

February 4th 2024

World Cancer Day is held every year on February 4th, prompting individuals across the globe to expand awareness within cancer care.

Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk Relapsed/Refractory Multiple Myeloma

February 3rd 2024

Hans Lee, MD, discusses updated data from the LINKER-MM1 study in heavily pretreated relapsed/refractory multiple myeloma.

Lenvatinib/Pembrolizumab Maintained Beneficial Outcomes When Evaluated by Tumor Size in RCC

February 2nd 2024

Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.

FDA Grants Priority Review to Afami-Cel BLA in Advanced Synovial Sarcoma

February 1st 2024

The FDA has accepted for priority review the BLA seeking the approval of afamitresgene autoleucel for the treatment of advanced synovial sarcoma.

Momelotinib Approved in Europe for Myelofibrosis With Anemia

January 29th 2024

Momelotinib gets market authorization from the European Commission for patients with MPNs and disease-related splenomegaly or moderate to severe anemia.

CD19 CAR T Cells Plus Acalabrutinib Shows Early Activity in Relapsed/Refractory MCL

January 29th 2024

CD19 CAR T cell therapy plus acalabrutinib demonstrated early efficacy in patients with relapsed/refractory mantle cell lymphoma.